Riley Researcher Tapped for Education Role
A Riley Children’s Foundation-supported cancer investigator in Riley Hospital for Children’s research facility, the Wells Center for Pediatric Research, has been selected to join the Education Board at the American Health Council. Mark R. Kelley, Ph.D., will be sharing his knowledge and expertise on DNA repair and cancer drug development.
As a faculty member of the Indiana University School of Medicine for more 24 years, Dr. Kelley directs basic and translational research in pediatric and adult oncology and mentors graduate students, interns, medical fellows and post doctorates. Dr. Kelley’s lab focuses on a critical and novel cancer signaling node, APE1/Ref-1. His biotech start-up, Apexian Pharmaceuticals, is working to advance his findings so they can help patients, and Phase 1 clinical trials will begin soon. This approach uses the APE1/Ref-1 target to produce new drugs to fight some of the deadliest and hardest-to-treat cancers. Related research is also investigating how this approach may help prevent chemotherapy-induced peripheral neuropathy (CIPN).
Due to his commitment to research, Dr. Kelley has most recently been awarded the Betty and Earl Herr Chair in Pediatric Oncology Research, Translating Research Into Practice (TRIP) Scholar, Innovation to Enterprise Commercialization Award 2015, and Bantz-Petronio Translating Research Into Practice Award 2017. Dr. Kelley plans to continue his bench to clinic studies, begin Phase 1 trials in conjunction with Apexian Pharmaceuticals with APX3330, and continue mentoring the next generation of scientists.